Loading...
•
Dec 31, 2024
Ionis Q4 2024 Earnings Report
Ionis Q4 2024 Earnings Report showed a revenue decline and increased losses, but the company exceeded guidance and launched its first independent medicine.
Key Takeaways
Ionis Pharmaceuticals reported Q4 2024 revenue of $227,000,000, a 30.15% decline YoY. The company posted a net loss of $104,000,000, compared to a loss of $9,000,000 in Q4 2023. Despite these losses, Ionis exceeded its financial guidance and launched TRYNGOLZA, its first independently commercialized product.
Revenue declined by 30.15% YoY to $227,000,000.
Net loss increased to $104,000,000 from $9,000,000 YoY.
The company launched TRYNGOLZA, its first independent product.
Ionis exceeded its 2024 financial guidance.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comWAINUA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
Ionis expects a shift toward increasing commercial revenue in 2025, investing in independent product launches while maintaining a strong financial position.
Positive Outlook
- Revenue expected to exceed $600,000,000 in 2025.
- Company shifting toward increasing commercial revenue sources.
- Continued investment in TRYNGOLZA and upcoming product launches.
- Cash position expected to remain strong at ~$1,700,000,000.
- Pipeline progress with multiple upcoming clinical milestones.
Challenges Ahead
- Operating loss expected to be below $495,000,000.
- R&D expenses expected to remain high due to ongoing trials.
- Market acceptance of new products remains uncertain.
- Regulatory risks could impact launch timelines.
- Potential competition from other biotechnology firms.